Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazosentan TQT Study in Healthy Subjects
NCT03657446Phase 1Completed
- Sponsor
- Idorsia
- Start
- Sep 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of clazosentan in cerebral vasospasm and aneurysmal subarachnoid hemorrhage (SAH) (6 arms), sponsored by Idorsia. Primary endpoint: Placebo-corrected change-from-baseline QTcF. Started Sep 2018; status: completed.
02
Drugs
clazosentan
03
Conditions
cerebral vasospasmaneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT03657446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657446.